Yahoo
NasdaqGS - Nasdaq Real Time Price USD

CeriBell, Inc. (CBLL)

26.58 -1.24 (-4.46%)
At close: October 30 at 4:00:02 PM EDT
26.58 0.00 (0.00%)
After hours: October 30 at 4:00:16 PM EDT
Trade CBLL on Coinbase
CBLL Q3 2026 earnings call
November 3, 2026 at 4:30 PM EST
Chart Range Bar
Loading chart for CBLL
  • Previous Close 27.82
  • Open 27.48
  • Bid 26.53 x 100
  • Ask 33.51 x 200
  • Day's Range 26.01 - 27.61
  • 52 Week Range 10.85 - 28.19
  • Volume 469,687
  • Avg. Volume 431,373
  • Market Cap (intraday) 1.02B
  • Beta (5Y Monthly) 0.93
  • PE Ratio (TTM) --
  • EPS (TTM) -1.76
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 28.57
  • Motley Fool Rating Bullish

CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.

www.ceribell.com

327

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CBLL
21.20%
S&P 500 (^GSPC)
10.73%

1-Year Return

CBLL
134.81%
S&P 500 (^GSPC)
11.11%

3-Year Return

CBLL
14.27%
S&P 500 (^GSPC)
81.91%

5-Year Return

CBLL
14.27%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 28.1M
Earnings -19.27M
Profit Margin -68.58%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-10M
0
10M
20M
-70.0%
-65.0%
-60.0%
-55.0%

Analyst Insights

View More

Analyst Price Targets

24.00 Low
28.57 Average
26.58 Current
33.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/2/2026
Analyst TD Cowen
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 29 -> 33

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -64.73%

  • Return on Assets (ttm)

    -23.38%

  • Return on Equity (ttm)

    -43.93%

  • Revenue (ttm)

    101.96M

  • Net Income Avi to Common (ttm)

    -66M

  • Diluted EPS (ttm)

    -1.76

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    129.26M

  • Total Debt/Equity (mrq)

    17.08%

  • Levered Free Cash Flow (ttm)

    -33.05M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: